Nearly 400 members of the S&P 500 were "oversold" on a statistical basis at the end of last week and therefore should rebound this week.» Read More
NEW YORK— The U.S. stock market endured its worst performance in 18 months on Thursday, driven lower by another slump in Chinese shares and heavy selling by technical traders. The global rout started in China, where sharp declines in energy and property stocks pushed the Shanghai Composite down more than 3 percent. "The emerging markets really got slammed...
Data from Axioma show that the most concentrated risk in the Nasdaq 100 is confined to the top six stocks.
Despite muted returns for the S&P 500 in 2015, analysts on Wall Street just love these stocks.
July 29- Express Scripts Holding Co, the largest pharmacy benefit manager in the United States, on Wednesday said the cost of potent, newly approved cholesterol drugs could "wreak financial havoc" among its clients. Express Scripts, which administers drug benefits for employers and health plans and also runs large mail-order pharmacies, has been challenging...
U.S. stocks closed higher after the Fed kept rates unchanged and the continued recovery in oil prices encouraged investor sentiment.
*Fed statement expected at 2 p.m. ET. *Yelp falls sharply after revenue misses expectations. The statement is expected at 2 p.m. ET.
Some of the names on the move ahead of the open.
July 29- U.S. stock index futures rose on Wednesday on hopes that Beijing could stem the rout in its markets and ahead of a statement from the U.S. *In a recent congressional testimony, Fed Chair Janet Yellen neither ruled out a September interest rate hike nor guided the market toward thinking it was a done deal. The statement is expected at 2 p.m. ET.
July 28- Gilead Sciences Inc said on Tuesday sales of its hepatitis C drugs hit a record of nearly $5 billion, surpassing Wall Street estimates as strong demand offset pricing pressures and restrictions on patient use from U.S. health insurers. Excluding items, Gilead earned $3.15 a share in the second quarter, beating the $2.71 average forecast by Wall Street...
The "Fast Money" traders awarded their final grades to the Gilead, Twitter and Yelp following their quarterly earnings reports.
Check out the companies making headlines after the bell Tuesday: Yelp, Akamai, Panera & more.
Gilead blew past top and bottom line expectations on the strength of strong sales for its hepatitis C treatments.
July 28- Gilead Sciences Inc said on Tuesday its quarterly net profit rose 32 percent, driven by sales of hepatitis C drugs that beat Wall Street estimates. Looking ahead, Gilead raised its outlook for full-year 2015 product sales by $1 billion to between $29 billion and $30 billion. Excluding items, Gilead earned $3.15 a share in the second quarter, exceeding the...
*Focus on corporate results eclipses China worry. *Twitter and Gilead up after the bell; Yelp drops. "The S&P has had five down days in a row and a lot of people are starting to nibble," said Michael Matousek, head trader at U.S. Global Investors Inc in San Antonio, which manages about $1 billion.
The "Halftime Report" traders give their trades on earnings for the second half.
The Fed meets next week, but a commodities meltdown and earnings season are adding to concerns about global growth and may steal some of its thunder.
Jim Cramer lays out his game plan next week. It will all about the Fed, Fed, Fed with a side of China.
One large pharmacy benefit manager warns that costs from new PCSK9 drugs could reach as high as $150 billion annually.
July 24- The U.S. Food and Drug Administration on Friday approved two treatments for less common forms of hepatitis C virus infections. The regulator cleared AbbVie Inc's Technivie, which targets HCV genotype 4 infections, and Bristol-Myers Squibb Co's Daklinza, used to treat HCV genotype 3 infections. Technivie, includes the same cocktail of drugs that...
*AbbVie CEO sees 2015 Humira growth in mid-teens. July 24 (Reuters)- AbbVie Inc reported quarterly revenue that missed analysts' estimates for the first time in six quarters, sparking concerns over slowing sales growth for its flagship arthritis drug, Humira. AbbVie reported total Humira sales of $3.54 billion for the quarter ended June 30, a 7.6 percent fall from a...